Your AI-Trained Oncology Knowledge Connection!
Sara Tolaney, MD, MPH introduces the 2022 Journal of Clinical Oncology preprint publication, “Sacituzumab Govitecan in Hormone Receptor–Positive/ Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer” and invites Martin Dietrich, MD, PhD and Gregory Vidal, MD, PhD to comment on the typical patients with hormone receptor–positive (HR+)/human epidermal growth factor receptor 2–negative (HER2-) metastatic breast cancer (mBC) who they see in their clinical practice.
Expert oncologists look toward future utilization of circulating tumor DNA testing and consider how the field of oncology may evolve.
Shared insight on how circulating tumor DNA may be used in real-world clinical practice to improve the value of cancer care.
Focusing broadly on breast cancer, expert oncologists detail how ctDNA may impact patient monitoring and treatment decisions moving forward.
Moving on to the second patient scenario, panelists elucidate the value of ctDNA in patients with triple-negative breast cancer.
In the context of clinical trial data and personal experience, experts weigh the value of circulating tumor DNA as a tool in cancer care.
Experts share their perspective on clinical trial data driving the use of circulating tumor DNA in various settings of cancer care.
Focusing on breast cancer, lung cancer, and GI cancers respectively, expert oncologists review the utility of circulating tumor DNA assays.
Expert panelists elucidate the mechanisms of ctDNA and MRD testing, providing a broad perspective on how they are used in cancer care.
Shared insight on the potential roles of ctDNA and MRD testing in the monitoring and treatment of patients with colorectal cancer.
Centering discussion on a patient scenario of stage II colorectal cancer, expert oncologists consider how ctDNA may inform use of adjuvant chemotherapy in this setting.
